Vimarsana
Biggest News Aggregation in the World

Page 2 - Richard Scheller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Richard Scheller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Richard Scheller Today - Breaking & Trending Today

CEO Anne Wojcicki on turning 23andMe into a 'full-fledged biotech' - Vimarsana News

CEO Anne Wojcicki on turning 23andMe into a 'full-fledged biotech'

BioPharma

Velia Therapeutics Announces Appointment of Veteran Drug Developer, John McHutchison, AO, MD as President and Chief Executive Officer - Vimarsana News

Velia Therapeutics Announces Appointment of Veteran Drug Developer, John McHutchison, AO, MD as President and Chief Executive Officer

Dr. McHutchison is a world-renowned physician, scientist, and drug developer who has led the research and development of numerous marketed therapies for...

Stanford president dodges research misconduct questions - Vimarsana News

Stanford president dodges research misconduct questions

Stanford President Marc Tessier-Lavigne has declined to answer dozens of questions and made statements about his research that contradict accounts of fellow researchers, Genentech and the scientific record. Meanwhile, professors have publicly questioned his ability to lead as he grapples with mounting allegations.

Allegations against Stanford president corroborated to board - Vimarsana News

Allegations against Stanford president corroborated to board

An email contained additional allegations about Marc Tessier-Lavigne’s Alzheimer’s research and the 2011 internal review that former colleagues allege uncovered falsification.

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update - Vimarsana News

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

23.02.2023 - –Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 ...